Kaleido Biosciences, Inc.
KLDO · OTC
12/31/2021 | 9/30/2021 | 6/30/2021 | 3/31/2021 | |
|---|---|---|---|---|
| Market Cap | $100,045 | $232,474 | $316,487 | $321,510 |
| - Cash | $38,474 | $55,657 | $71,979 | $92,362 |
| + Debt | $21,694 | $21,516 | $21,344 | $21,192 |
| Enterprise Value | $83,265 | $198,333 | $265,852 | $250,340 |
| Revenue | $492 | $104 | $211 | $297 |
| % Growth | 373.1% | -50.7% | -29% | – |
| Gross Profit | $492 | $104 | $211 | $297 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$18,953 | -$21,782 | -$22,601 | -$21,756 |
| % Margin | -3,852.2% | -20,944.2% | -10,711.4% | -7,325.3% |
| Net Income | -$21,119 | -$22,491 | -$24,593 | -$23,745 |
| % Margin | -4,292.5% | -21,626% | -11,655.5% | -7,994.9% |
| EPS Diluted | -0.001 | -0.53 | -0.58 | -0.6 |
| % Growth | 99.9% | 8.6% | 3.3% | – |
| Operating Cash Flow | -$17,160 | -$15,877 | -$20,083 | -$23,974 |
| Capital Expenditures | -$436 | -$431 | -$232 | -$30 |
| Free Cash Flow | -$17,596 | -$16,308 | -$20,315 | -$24,004 |